Equities

Eom Pharmaceutical Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
IMUC:PKL

Eom Pharmaceutical Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.1789
  • Today's Change0.00 / 0.00%
  • Shares traded301.00
  • 1 Year change+27.79%
  • Beta0.5439
Data delayed at least 15 minutes, as of Feb 10 2026 16:45 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

EOM Pharmaceutical Holdings, Inc., through its wholly owned subsidiary EOM Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its pipeline includes its lead compound EOM613, an investigational novel dynamically dual-acting immunomodulator. EOM613 is a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects. Human cell culture studies demonstrate that EOM613 can suppress or stimulate monocytes and macrophages depending on the activation state and environment of those key immune cells, resulting in either further activation or suppression. Its pipeline also includes EOM147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases.

  • Revenue in USD (TTM)0.00
  • Net income in USD-4.93m
  • Incorporated1987
  • Employees3.00
  • Location
    Eom Pharmaceutical Holdings Inc30721 Russell Ranch Road, Suite 140WESTLAKE VILLAGE 91362United StatesUSA
  • Phone+1 (818) 264-2300
  • Fax+1 (302) 655-5049
  • Websitehttps://imuc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Apollomics Inc8.50m-31.19m20.58m13.00------2.42-26.61-26.618.01-3.990.3721----653,846.10-136.51---276.35-------366.92--------------68.80------
Jupiter Neurosciences Inc0.00-7.60m21.16m4.00--367.13-----0.2296-0.22960.000.00170.00----0.00-570.85-383.24-----------902.90----0.7183------49.00------
Neuphoria Therapeutics Inc15.66m-9.47m21.78m7.00--0.7632--1.39-3.77-3.778.425.310.6233--266.102,237,532.00-37.69-35.39-44.48-39.01-----60.47-375.66----0.0026----246.6597.61------
Aspira Women's Health Inc9.34m-10.80m21.78m66.00------2.33-0.3782-0.37820.3387-0.10181.5511.797.26141,469.70-179.16-116.24-903.68-168.6563.9050.98-115.66-287.591.32-189.81----0.305915.1421.55---22.58--
NanoViricides, Inc0.00-8.13m21.78m7.00--2.47-----0.5115-0.51150.000.40870.00----0.00-80.86-43.34-94.03-45.34------------0.00-------14.14--45.82--
Polyrizon Ltd0.00-1.16m21.95m1.00--0.7345-----582.43-582.430.0018.750.00----0.00-11.74-80.79-12.20-179.91------------0.00-------139.91------
Finch Therapeutics Group Inc0.00-14.17m22.08m18.00--1.55-----8.82-8.820.008.860.00-------25.20---28.80--------------0.00---87.57--34.80------
Vistagen Therapeutics Inc736.00k-62.24m22.31m59.00--0.3311--30.31-1.91-1.910.02271.710.008----13,142.86-67.86-55.19-76.71-59.56-----8,455.98-5,842.62----0.0098---54.32---75.12------
Serina Therapeutics Inc130.00k-18.59m22.39m12.00------172.27-1.88-1.880.01330.16690.0131----10,833.33-187.74-188.54---------14,331.54-7,513.03---730.130.6444---60.56-49.6424.74---49.05--
Intensity Therapeutics Inc0.00-11.74m22.49m5.00--2.54-----0.638-0.6380.000.14720.00----0.00-158.62-117.05-230.00-201.39------------0.00-------37.14------
Eom Pharmaceutical Holdings Inc0.00-4.93m22.63m3.00---------0.0435-0.04350.00-0.0212------0.00---126.34---171.37------------7.41-------254.37------
Skye Bioscience Inc0.00-51.23m23.09m----0.6798-----1.29-1.290.001.060.00-------83.39-139.20-94.11-262.81------------0.00------29.43------
Senti Biosciences Inc0.00-47.58m23.20m34.00--2.86-----2.80-2.800.000.30890.00----0.00-86.19-50.97-106.55-57.59-------2,565.78----0.00---100.00--36.71---58.03--
Regentis Biomaterials Ltd0.00-5.20m23.88m-----------1.00-1.000.00-1.870.00-------1,548.81--------------------------226.60------
LAMY0.00106.70k24.50m--25.51--201.80--0.01370.01370.00-0.00450.00------763.23-----------------------67.39--299.15------
Lunai Bioworks Inc0.00-130.98m24.84m29.00---------7.51-7.510.00-0.56260.00----0.00-203.39-75.79-304.47-85.18-----------28.85---------101.31------
Data as of Feb 10 2026. Currency figures normalised to Eom Pharmaceutical Holdings Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.